Clinical Trial Update: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial comparing ocular pain and inflammation after injections of Lucentis (ranibizumab) versus Eylea (aflibercept) in neovascular age-related macula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Arshad Khanani | Conditions: Neovascular Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-03